Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
17 Jan 2017 FDA Approves Bevacizumab Plus Chemotherapy, Followed by Bevacizumab Alone, for the Treatment of Patients with Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
16 Jan 2017 FDA Grants Priority Review for Atezolizumab in First-Line Treatment of Patients With Urothelial Carcinoma Who are Not Eligible for Cisplatin Chemotherapy Genitourinary cancers - Cancer Immunology and Immunotherapy
13 Jan 2017 Tailored Scientific Advice to Support Step-by-Step Development of New Biosimilars Bioethics, legal and economic issues
12 Jan 2017 NICE Issues Recommendations for Pembrolizumab in PD-L1-positive Locally Advanced or Metastatic NSCLC After Chemotherapy Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
10 Jan 2017 EU-funded MoTriColor Project for Patients with Metastatic CRC Translational research - Gastrointestinal cancers
09 Jan 2017 NICE Recommends Pertuzumab for the Neoadjuvant Treatment of HER2-positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
23 Dec 2016 EMA Adopts a New Indication for 5-Aminolevulinic Acid Melanoma and other skin tumours - Anticancer agents & Biologic therapy
21 Dec 2016 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Chlormethine Haematologic malignancies - Anticancer agents & Biologic therapy
21 Dec 2016 FDA Grants Accelerated Approval to Rucaparib for Previously Treated, BRCA Mutated Advanced Ovarian Cancer Personalised medicine - Gynaecologic malignancies - Anticancer agents & Biologic therapy
20 Dec 2016 EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab Haematologic malignancies - Anticancer agents & Biologic therapy
19 Dec 2016 EMA Recommends to Extend Indications for Pembrolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
18 Dec 2016 ESMO Asia 2016 Press Release: Immunotherapy with Pembrolizumab Deemed Cost-Effective for Advanced Melanoma Patients in Hong Kong Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
18 Dec 2016 ESMO Asia 2016 Press Release: Routine Blood Test Predicts How Long Cancer Patients Will Survive Palliative and supportive care
18 Dec 2016 ESMO Asia 2016 Press Release: Cancer Costs Leaving Patients in Debt Bioethics, legal and economic issues
18 Dec 2016 ESMO Asia 2016 Press Release: Depressed Patients Are Less Responsive to Chemotherapy Anticancer agents & Biologic therapy